» Articles » PMID: 31141817

Role of RGS12 in the Differential Regulation of Kappa Opioid Receptor-dependent Signaling and Behavior

Overview
Date 2019 May 30
PMID 31141817
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Kappa opioid receptor (KOR) agonists show promise in ameliorating disorders, such as addiction and chronic pain, but are limited by dysphoric and aversive side effects. Clinically beneficial effects of KOR agonists (e.g., analgesia) are predominantly mediated by heterotrimeric G protein signaling, whereas β-arrestin signaling is considered central to their detrimental side effects (e.g., dysphoria/aversion). Here we show that Regulator of G protein Signaling-12 (RGS12), via independent signaling mechanisms, simultaneously attenuates G protein signaling and augments β-arrestin signaling downstream of KOR, exhibiting considerable selectivity in its actions for KOR over other opioid receptors. We previously reported that RGS12-null mice exhibit increased dopamine transporter-mediated dopamine (DA) uptake in the ventral (vSTR), but not dorsal striatum (dSTR), as well as reduced psychostimulant-induced hyperlocomotion; in the current study, we found that these phenotypes are reversed following KOR antagonism. Fast-scan cyclic voltammetry studies of dopamine (DA) release and reuptake suggest that striatal disruptions to KOR-dependent DAergic neurotransmission in RGS12-null mice are restricted to the nucleus accumbens. In both ventral striatal tissue and transfected cells, RGS12 and KOR are seen to interact within a protein complex. Ventral striatal-specific increases in KOR levels and KOR-induced G protein activation are seen in RGS12-null mice, as well as enhanced sensitivity to KOR agonist-induced hypolocomotion and analgesia-G protein signaling-dependent behaviors; a ventral striatal-specific increase in KOR levels was also observed in β-arrestin-2-deficient mice, highlighting the importance of β-arrestin signaling to establishing steady-state KOR levels in this particular brain region. Conversely, RGS12-null mice exhibited attenuated KOR-induced conditioned place aversion (considered a β-arrestin signaling-dependent behavior), consistent with the augmented KOR-mediated β-arrestin signaling seen upon RGS12 over-expression. Collectively, our findings highlight a role for RGS12 as a novel, differential regulator of both G protein-dependent and -independent signaling downstream of KOR activation.

Citing Articles

Molecular Modeling and In Vitro Functional Analysis of the RGS12 PDZ Domain Variant Associated with High-Penetrance Familial Bipolar Disorder.

Agogo-Mawuli P, Mendez J, Oestreich E, Bosch D, Siderovski D Int J Mol Sci. 2024; 25(21).

PMID: 39518985 PMC: 11546610. DOI: 10.3390/ijms252111431.


βγ G-proteins, but not regulators of G-protein signaling 4, modulate opioid-induced respiratory rate depression.

Danaf J, da Silveira Scarpellini C, Montandon G Front Physiol. 2023; 14:1043581.

PMID: 37089428 PMC: 10117644. DOI: 10.3389/fphys.2023.1043581.


Characterization of a Potential KOR/DOR Dual Agonist with No Apparent Abuse Liability via a Complementary Structure-Activity Relationship Study on Nalfurafine Analogues.

Li M, Stevens D, Arriaga M, Townsend E, Mendez R, Blajkevch N ACS Chem Neurosci. 2022; 13(24):3608-3628.

PMID: 36449691 PMC: 10243363. DOI: 10.1021/acschemneuro.2c00526.


The stability of tastant detection by mouse lingual chemosensory tissue requires Regulator of G protein Signaling-21 (RGS21).

Schroer A, Branyan K, Gross J, Chantler P, Kimple A, Vandenbeuch A Chem Senses. 2021; 46.

PMID: 34718440 PMC: 8785950. DOI: 10.1093/chemse/bjab048.


Short stature and combined immunodeficiency associated with mutations in RGS10.

Chinn I, Xie Z, Chan E, Nagata B, Koval A, Chen W Sci Signal. 2021; 14(693).

PMID: 34315806 PMC: 8522579. DOI: 10.1126/scisignal.abc1940.


References
1.
Crowley N, Kash T . Kappa opioid receptor signaling in the brain: Circuitry and implications for treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2015; 62:51-60. PMC: 4465498. DOI: 10.1016/j.pnpbp.2015.01.001. View

2.
Chavkin C, Koob G . Dynorphin, Dysphoria, and Dependence: the Stress of Addiction. Neuropsychopharmacology. 2015; 41(1):373-4. PMC: 4677142. DOI: 10.1038/npp.2015.258. View

3.
Schindler A, Messinger D, Smith J, Shankar H, Gustin R, Schattauer S . Stress produces aversion and potentiates cocaine reward by releasing endogenous dynorphins in the ventral striatum to locally stimulate serotonin reuptake. J Neurosci. 2012; 32(49):17582-96. PMC: 3523715. DOI: 10.1523/JNEUROSCI.3220-12.2012. View

4.
Vant Veer A, Carlezon Jr W . Role of kappa-opioid receptors in stress and anxiety-related behavior. Psychopharmacology (Berl). 2013; 229(3):435-52. PMC: 3770816. DOI: 10.1007/s00213-013-3195-5. View

5.
Schenk S, Partridge B, Shippenberg T . U69593, a kappa-opioid agonist, decreases cocaine self-administration and decreases cocaine-produced drug-seeking. Psychopharmacology (Berl). 1999; 144(4):339-46. DOI: 10.1007/s002130051016. View